Skip to main content
. 2020 Dec 18;17(24):9514. doi: 10.3390/ijerph17249514

Figure A1.

Figure A1

Prevalence (%) of AD users, stratified by calendar year and AD molecule/class. Legend: AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagonlike peptide-1 receptor antagonists; SGLT2i = sodium–glucose linked transporter 2 inhibitors; Other oral combinations = fixed-dose combinations of glitazones + DPP4i and glitazones + sulfonylureas.